《公司業績》中國稀土(00769.HK)半年虧轉盈賺1,394萬元
中國稀土(00769.HK)公布截至今年6月底止中期業績,營業額4.39億元,按年升1%。虧轉盈賺1,393.9萬元,上年同期蝕1,137.2萬元;每股盈利0.6仙。不派息。
來自稀土分部的收入約2.84億元,和去年同期相若。然而銷售數量卻比去年同期減少約三成至約500噸。
期內,集團整體錄得毛利率約10%,較去年同期的約4%有所改善。
展望下半年,在中美貿易磨擦持續的背景下,中國將堅定推進科技創新,進一步擴大國內市場需求,並有望增加儲備,以維護中國稀土在全球的戰略地位,為稀土行業長線發展造就有利條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.